Institut Català de la Salut
[García Castaño A, Pérez de Nanclares G] BioCruces Health Research Institute, Ciberer, Cruces University Hospital, Bizkaia, Spain. [Madariaga L] Pediatric Nephrology, Cruces University Hospital, Bizkaia, Spain. Department of Pediatrics, School of Medicine and Odontology, University of Basque Country UPV/EHU, Bizkaia, Spain. [Aguirre M] Pediatric Nephrology, Cruces University Hospital, Bizkaia, Spain. [Madrid Á, Chocrón S, Ariceta G] Servei de Nefrologia Pediàtrica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-04-27T11:14:00Z
2021-04-27T11:14:00Z
2017-03-13
Excreció; Genètica humana; Mutació
Excreción; Genética humana; Mutación
Excretion; Human genetics; Mutation
Introduction Type III Bartter syndrome (BS) is an autosomal recessive renal tubule disorder caused by loss-of-function mutations in the CLCNKB gene, which encodes the chloride channel protein ClC-Kb. In this study, we carried out a complete clinical and genetic characterization in a cohort of 30 patients, one of the largest series described. By comparing with other published populations, and considering that 80% of our patients presented the p.Ala204Thr Spanish founder mutation presumably associated with a common phenotype, we aimed to test the hypothesis that allelic differences could explain the wide phenotypic variability observed in patients with type III BS. Methods Clinical data were retrieved from the referral centers. The exon regions and flanking intronic sequences of the CLCNKB gene were screened for mutations by polymerase chain reaction (PCR) followed by direct Sanger sequencing. Presence of gross deletions or duplications in the region was checked for by MLPA and QMPSF analyses. Results Polyuria, polydipsia and dehydration were the main common symptoms. Metabolic alkalosis and hypokalemia of renal origin were detected in all patients at diagnosis. Calciuria levels were variable: hypercalciuria was detected in 31% of patients, while 23% had hypocalciuria. Nephrocalcinosis was diagnosed in 20% of the cohort. Two novel CLCNKB mutations were identified: a small homozygous deletion (c.753delG) in one patient and a small deletion (c.1026delC) in another. The latter was present in compound heterozygosis with the already previously described p.Glu442Gly mutation. No phenotypic association was obtained regarding the genotype. Conclusion A poor correlation was found between a specific type of mutation in the CLCNKB gene and type III BS phenotype. Importantly, two CLCNKB mutations not previously described were found in our cohort
This study was supported by two grants (PI09/90888 and PI11/01412) from the FIS of the Instituto de Salud Carlos III, Madrid, Spain, the Department of Health of the Basque Government (2014111064), and the Department of Education of the Basque Government (IT795-13).
Article
Published version
English
Malalties congènites; Ronyons - Malalties; DISEASES::Endocrine System Diseases::Adrenal Gland Diseases::Adrenocortical Hyperfunction::Hyperaldosteronism::Bartter Syndrome; Other subheadings::Other subheadings::Other subheadings::/genetics; ENFERMEDADES::enfermedades del sistema endocrino::enfermedades de las glándulas suprarrenales::hiperfunción corticosuprarrenal::hiperaldosteronismo::síndrome de Bartter; Otros calificadores::Otros calificadores::Otros calificadores::/genética
Public Library of Science
PLoS ONE;12(3)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173581
info:eu-repo/grantAgreement/ES/1PN/2008-20117PI09%2F90888
info:eu-repo/grantAgreement/ES/2PN/2008-2011/PI11%2F01412
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]